Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — Q1 2021 Earnings Presentation
33 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2021
Slide 1: 1Q2021 Results Update
1Q2021 Results Update
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
List of Figures Corporate Overview 04 Near Term and Long Term Strategy 18 Company Highlight 05 Network Expansion Plan 19 Financial Update 29 Company History 06 Leader in Next Gen Technology 20 Gross Profit and Net Income 30 Shareholder Composition 07 Business Update 21 COGS and OPEX 31 Market Overvi
Slide 4: Corporate Overview
Corporate Overview 1
Slide 5: Company Highlight
IDR 625.5 Billion • Established in 1973 with strong track record for more than 48 years experiences in 1Q2021 Revenue Clinical Lab Industry • Pioneer and the leading clinical laboratory >833K testing Company with the most recognized Brand in Indonesia • Largest private independent clinical lab Patie
Slide 6: Strong Track Record in Clinical Laboratory Testing
Strong Track Record in Clinical Laboratory Testing The first private lab in Indonesia Received SMK3 accreditation Established professional Established that using fully automated Cobas and OHSAS 2015, along with management team Prodia ChildLab 6800 for RT-PCR COVID-19 Partnerships the Award a
Slide 7: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 8: Market Overview
Market Overview 2
Slide 9: Indonesia Economic Outlook
Indonesia Economic Outlook 4.0% – 5.0% Indonesia’s GDP Growth Projection for 2021 Indonesia’s economic recovery and improvement in 2021 GDP Growth Projection 2021 will be supported by the Indonesia World effectiveness of Indonesia’s Govt’ 5.0% N/A COVID-19 pandemic World Bank 4.4% 4.0% containment e
Slide 10: Investment Highlight
Investment Highlight 3
Slide 11: 1. Largest Network & Market Share in Independent Clinical Lab Industry
1. Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2018 & 2019) (Billion IDR) 3YRS CAGR 8.3% 38.8% 39.2% 4,551 3YRS CAGR 4,222 3,883 9.1% 28.2% 2018 26.9% 2019 1,466 1,600 1,744 33.0% 33.9% 2017 2
Slide 12: 2. Strong Operational Track Record
2. Strong Operational Track Record VISITS REVENUE CAGR CAGR 5.4% 8.4% Prodia has generated continuous revenue growth 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 and increasing number of visits that supported REVENUE PER VISIT Company’s profitability EBITDA CAGR 2.8% CAGR 21.5% 2016 2017 2018 2
Slide 13: 3. Comprehensive Service Offering with Multiple Customer Segments
3. Comprehensive Service Offering with Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics One-stop shop, offering the most Esoteric Testing Referral Lab Services Doctor Consultation comprehensive Predictive, Preventive, General Medical Preventive Treatment range of c
Slide 14: 4. Scalable Hub and Spoke Business Model
4. Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved “Hub and spoke” model Centralized information Prodia Clinical Labs, offers scalable platform Prodia Referral with integrated IT Hospitals and Other Clinics platform
Slide 15: 5. Strong Relationship with Medical Community
5. Strong Relationship with Medical Community Strong relationships through the work of more Introduced new tests, such as NIPT ProSafe, Amino Acid Profile, than 500 Marketing and Laboratory Fatty Acid Profile, CArisk, DIArisk, Liquid biopsy EGFR Mutation, New Information Service personnel Born Scree
Slide 16: 6. Experienced Senior Leadership and Management Team
6. Experienced Senior Leadership and Management Team Professional Management Team with Strong Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 48 Experience 48 Experience 38 Experience 25 Experience 25 Experience Andi Gunawan Endang Kemal Imam Ke
Slide 17: Growth Strategy
Growth Strategy 4
Slide 18: Growth Strategy
Growth Strategy Expand our presence and grow Strengthen digital capabilities our network of outlets in both to enable business growth physical and digital channel in Indonesia Develop data & analytics A Near-term capabilities to create business values Upgrade existing clinical laboratories to provid
Slide 19: Prodia's Network Expansion Plan 2016 - 2021
Prodia’s Network Expansion Plan 2016 - 2021 1 2 3 4 Expand Network Upgrade Enhance Focus on of Outlets Clinical Labs Operating Quality 31 regional referral labs Upgrade up to 39 Efficiency clinical labs to PHC3 Clinics Up to 33 additional clinical labs over next five years 24 Clinical Lab Improvemen
Slide 20: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 21: Business Update
Business Update 5
Slide 22: Response to COVID-19 Pandemic
Response to COVID-19 Pandemic Develop COVID-19 Related Test: PCR, Antibody, Antigen testing Expand More Collaboration and Partnership: More Hospital Referral especially for COVID-19 Create New Ways of Service: test and for Swab Sampling Cleanliness, Safety, Convenience Revisit Budget and Strategy: B
Slide 23: Deliver Solution for Customer Needs
DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer’s Voice Services & Lab Online Marketing Product Lab Testing In Facilities and Education Innovation COVID-19 Pandemic Activities • Prodia Mobile • Digital • Complete Testing from • COVID-19 Testing • Home/Office Serv
Slide 24: Digital Transformation to Fulfill Customer Needs
Digital Transformation to Fulfill Customer Needs > > Prodia has enhanced its digital platform services New Prodia Mobile Ver. 3 – Launched in Jan 2021 24
Slide 25: Customer Centric Model
Customer Centric Model eRegistration New Innovation & Enhancement Prodia in your Car Service Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners • Clinical Pathologists Tele-Health* • Internist • Clinical Nutritionist • Sport Medicine 25
Slide 26: Outlet Development
Outlet Development 2021 Outlet 2016-2021 Outlet Development Development Target 259 292 287 267 269 1-2 20 283 Clinical Labs POC Outlets 5 7 4** 4** 2 4** 11 14 14 12 9 11 Total Outlet 130 128 122 103 106 1-2 1 118 Specialty Clinics Hospital Lab Hospital Labs Specialty Clinic 129 136 143 147* 148* 14
Slide 27: 3 New Tests Launched in 1Q2021
Predictive, Preventive & Screening Targeted Diagnostic Pharmacogenomics Therapy 1. NIPT (ProSafe) 26. ADMA/SDMA 31. Jak2 Mutation 45.Jak 2 Mutation 55. Warfarin Indiv Test 2. Telomere Analysis 27. Prodia Skin and 32. Kidney Stone Analysis (FTIR) 46. Mutation EGFR (CYP2C9 & VCORC1 3. Vitamin A & E Ha
Slide 28: 1Q2021 Revenue
1Q2021 Revenue Quarterly Revenue Revenue (Unaudited) (Unaudited) in IDR Billion in IDR Billion FY16-FY20 CAGR +8.4% 1Q16-1Q21 CAGR +15.0% 2021 2020 2019 2018 2017 2016 • Revenue grew sharply by +59.8% in 4Q20, 1Q21 yoy, mostly 1Q21, 671.3 1,873.4 1Q20-1Q21 driven by walk in, 1,744.3 625.5 doctor ref
Slide 29: Financial Update
Financial Update 6
Slide 30: 1Q2021 Gross Profit & Net Income (Unaudited)
1Q2021 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY17-FY20 CAGR +7.0% 1Q17-1Q21 CAGR +19.4% FY17-FY20 CAGR +21.2% 1Q17-1Q21 CAGR +48.9% 1Q20-1Q21 1Q20-1Q21 growth +74.1% growth +356.4% 1,041.0 1,046.2 268.7 942.8 853.5 62.3% 210.3 25.4% 59.1% 150
Slide 31: 1Q2021 COGS & OPEX (Unaudited)
1Q2021 COGS & OPEX (Unaudited) COGS (in IDR Billion) OPEX (in IDR Billion) FY16-FY20 CAGR+10.0% 1Q17-1Q21 CAGR+14.0% FY16-FY20 CAGR +3.3% 1Q17-1Q21 CAGR +6.6% 0 1Q20-1Q21 1,000 50.0% 70.0% 827.2 827 1Q20-1Q21 growth +40.7% 770 713 746 growth +1.5% 0 703.3 800 676 50 656.9 125 46 60.0% 612.5 41 30 56
Slide 32: 1Q2021 Financial Summary (Unaudited)
1Q2021 Financial Summary (Unaudited) (in IDR Bn) 1Q2021 1Q2020 Change (in IDR Bn) 1Q2021 1Q2020 Change Revenue 625.5 391.4 +59.8% Total Asset 2,401.4 2,100.1 +14.3% Gross Profit 389.8 223.9 +74.1% Total Equity 1,953.5 1,687.6 +15.8% EBIT 192.9 29.1 +563.0% EBT 201.1 41.1 +388.9% Net Income 158.7 34.
Slide 33: Thank You!
Thank You! For more information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150, Jakarta 10430, Indonesia Phone +6221-3144182 ext. 3774, 3775 www.prodia.co.id 33
PT Prodia Widyahusada — Q1 2021 Earnings Presentation on 6ix